PFIZER - IntraDay Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

IntraDay Trade Rating: 2.1

PFIZER’s current intraday outlook is not ideal. Despite its strong fundamentals (zero debt, solid ROCE/ROE), its technical and price-action indicators show weakening momentum, low volume interest, and expensive valuation for a short-term trade.

📉 Technical Sentiment

RSI: 37.8 → Approaching oversold, but not indicating strong reversal potential.

MACD: -72.3 → Deep negative territory, confirming bearish momentum.

Volume: 11.9K vs Avg 22.8K → Weak participation; lacking intraday liquidity.

🧭 Current Price Structure

Trading Price: ₹5,277

Below DMA 50 (₹5,353), slightly above DMA 200 (₹4,988) → Trend bias is mixed, slightly negative.

52w Index: 57.3% → Moderate relative strength but off recent highs.

PE: 158 vs Industry PE 34.0 → Extremely overvalued short-term, making it vulnerable to profit booking.

⚙️ Intraday Trade Setup

❌ New Entry

Avoid initiating trades today unless volume picks up sharply and RSI moves above 42.

Conditional Buy Zone: ₹5,270–₹5,280 (only if volume >20K and MACD flattens)

Targets

₹5,310 → minor resistance

₹5,350 → stronger ceiling

Stop-Loss: ₹5,240

🔁 Already Holding

Exit Recommendation

If price fails to break ₹5,300 and RSI dips below 36, consider cutting losses.

If price rebounds above ₹5,310 and MACD compresses, trail stop to ₹5,275 and eye ₹5,350.

📌 Risk Watch

Valuation Concerns: PE far exceeds sector average—intraday buyers may hesitate.

Volume Slippage: Without pickup, even technical reversals may be muted.

Profit Data Unavailable: Lack of recent PAT insights weakens short-term confidence.

Institutional Moves: Slight accumulation (FII/DII), but not impactful enough intraday.

Let me know if you want to explore sectoral alternatives or build a quick momentum radar for pharma and healthcare tickers. There might be stronger setups brewing elsewhere 💊📊.

Edit in a page